Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”

Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet